Study ID: 9013
Study Title
- Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS
Teva Identifier
- 9013
ClinicalTrials.gov Identifier
- NCT00202995
Study Status
- Terminated
Trial Condition(s)
- Relapsing Remitting Multiple Sclerosis
Interventions
- Drug: Glatiramer Acetate | Drug: Betaseron | Drug: Rebif
Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
Gender
- Female, Male
Age Range
- 18 Years to 50 Years
Trial Duration
- 07/01/2004 - 10/01/2007
Phase
- Phase 4
Study Type
Interventional
